22 Jan 2018 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma Announces Appointment of Experienced Drug Development Clinician as Chief Medical Officer
Alderley Park, January 22 2018 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces the appointment of Dr. Andrew Saunders as Chief Medical Officer (CMO). Andrew has worked in the oncology field for over 25 years and has extensive experience in all aspects of the clinical development of oncology drugs.
Andrew will work with the research and development team at Redx, fronting the clinical development of RXC004, the Company's lead drug candidate. RXC004 is a novel, oral, potent small molecule Porcupine inhibitor, which targets the Wnt signalling pathway and is due to commence phase 1 clinical trials in the coming weeks.
Andrew joins Redx from Lytix Biopharma, a Norwegian immuno-oncology biotech, where he was CMO. During his career he has also held a number of increasingly senior positions in clinical development at both large pharma and biotech companies. These included Medical Director at Bioenvision Limited, an oncology biopharmaceutical company acquired by Genzyme (now part of Sanofi) for $345 million, Global Clinical Science Leader for Rituximab at F. Hoffman-La Roche and Clinical Research Physician at Eli-Lilly and Company. Andrew also founded and was Managing Director of Linden Oncology Limited, a consultancy providing strategic and clinical development oncology expertise to biotech and pharmaceutical companies. He obtained his medical degree from Trinity College Dublin and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, London.
Iain Ross, Chairman of Redx Pharma plc, commented, "We are very pleased to announce Andrew's appointment as Chief Medical Officer. He brings to the Company a wealth of relevant experience and expertise in the clinical development of oncology drugs. This will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase 1 study on lead compound RXC004 in the coming weeks.
"We are very excited by the potential of RXC004 to make a major difference in cancer treatment. We intend to progress RXC004 in the clinic both as a monotherapy and in combination with a checkpoint inhibitor. Therefore, we envisage that Andrew's recent experience in immuno-oncology combination trials will be particularly pertinent to the design and execution of future clinical trials with RXC004."
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Executive Chairman | |
Cantor Fitzgerald Europe (Nominated Advisor & Broker) | T: +44 20 7894 7000 |
Phil Davies | |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.